For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
After finishing at $61.51 in the prior trading day, Globus Medical Inc (NYSE: GMED) closed at $61.13, down -0.62%. In other words, the price has decreased by -$0.62 from its previous closing price. On the day, 0.76 million shares were traded. GMED stock price reached its highest trading level at $61.34 during the session, while it also had its lowest trading level at $60.335.
Ratios:
Our goal is to gain a better understanding of GMED by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 35.98 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 15.65. For the most recent quarter (mrq), Quick Ratio is recorded 2.26 and its Current Ratio is at 4.07. In the meantime, Its Debt-to-Equity ratio is 0.03 whereas as Long-Term Debt/Eq ratio is at 0.03.
On January 10, 2025, BofA Securities Upgraded its rating to Neutral which previously was Underperform but kept the price unchanged to $97.
Morgan Stanley Upgraded its Equal-Weight to Overweight on December 02, 2024, whereas the target price for the stock was revised from $83 to $100.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Feb 28 ’25 when RHOADS ANN D sold 7,500 shares for $78.68 per share. The transaction valued at 590,100 led to the insider holds 35,384 shares of the business.
RHOADS ANN D bought 7,500 shares of GMED for $590,000 on Feb 28 ’25. On Jan 10 ’25, another insider, Pfeil Keith W, who serves as the COO, CFO of the company, sold 14,167 shares for $88.29 each. As a result, the insider received 1,250,770 and left with 0 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, GMED now has a Market Capitalization of 8307383296 and an Enterprise Value of 8148012544. As of this moment, Globus’s Price-to-Earnings (P/E) ratio for their current fiscal year is 23.59, and their Forward P/E ratio for the next fiscal year is 16.69. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 2.48. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.14 while its Price-to-Book (P/B) ratio in mrq is 1.92. Its current Enterprise Value per Revenue stands at 3.102 whereas that against EBITDA is 11.078.
Stock Price History:
The Beta on a monthly basis for GMED is 1.17, which has changed by -0.1591472 over the last 52 weeks, in comparison to a change of 0.15109766 over the same period for the S&P500. Over the past 52 weeks, GMED has reached a high of $94.93, while it has fallen to a 52-week low of $51.79. The 50-Day Moving Average of the stock is 6.23%, while the 200-Day Moving Average is calculated to be -14.91%.
Shares Statistics:
The stock has traded on average 1.39M shares per day over the past 3-months and 1000650 shares per day over the last 10 days, according to various share statistics. A total of 112.62M shares are outstanding, with a floating share count of 111.81M. Insiders hold about 17.20% of the company’s shares, while institutions hold 85.39% stake in the company. Shares short for GMED as of 1755216000 were 5442884 with a Short Ratio of 3.91, compared to 1752537600 on 4516423. Therefore, it implies a Short% of Shares Outstanding of 5442884 and a Short% of Float of 5.41.
Earnings Estimates
The dynamic stock of Globus Medical Inc (GMED) is currently being evaluated by a team of 14.0 analysts, each contributing to its current rating.The consensus estimate for the next quarter is $0.89, with high estimates of $0.95 and low estimates of $0.72.
Analysts are recommending an EPS of between $3.35 and $3.15 for the fiscal current year, implying an average EPS of $3.22. EPS for the following year is $3.61, with 14.0 analysts recommending between $4.15 and $3.01.
Revenue Estimates
11 analysts predict $733.98M in revenue for the current quarter. It ranges from a high estimate of $747.02M to a low estimate of $728M. As of the current estimate, Globus Medical Inc’s year-ago sales were $625.71MFor the next quarter, 11 analysts are estimating revenue of $777.8M. There is a high estimate of $797.9M for the next quarter, whereas the lowest estimate is $760.58M.
A total of 13 analysts have provided revenue estimates for GMED’s current fiscal year. The highest revenue estimate was $2.89B, while the lowest revenue estimate was $2.84B, resulting in an average revenue estimate of $2.86B. In the same quarter a year ago, actual revenue was $2.52BBased on 13 analysts’ estimates, the company’s revenue will be $3.08B in the next fiscal year. The high estimate is $3.14B and the low estimate is $3B.
